Therapeutic targeting of tumor suppressor genes

5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft

(2015) Alexandra Borodovsky et al.   Oncotarget

Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.

(2015) Sevin Turcan et al.   Oncotarget

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

(2014) R. Bejar et al.   BLOOD

Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia

(2014) M. Rajasagi et al.   BLOOD

SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression

(2014) S. Wang et al.   CANCER RESEARCH

Predicting Cancer-Specific Vulnerability via Data-Driven Detection of Synthetic Lethality

(2014) Livnat Jerby-Arnon et al.   CELL

Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling

(2014) Susann Weissmueller et al.   CELL

Phase I Dendritic Cell p53 Peptide Vaccine for Head and Neck Cancer

(2014) P. J. Schuler et al.   CLINICAL CANCER RESEARCH

New and emerging HDAC inhibitors for cancer treatment

(2014) Alison C. West et al.   JOURNAL OF CLINICAL INVESTIGATION

Erratum: Drugging the p53 pathway: understanding the route to clinical efficacy

(2014) Kian Hoe Khoo et al.   NATURE REVIEWS DRUG DISCOVERY

Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer

(2014) J. J. Tao et al.   Science Signaling

Induction of sarcomas by mutant IDH2

(2013) C. Lu et al.   GENES & DEVELOPMENT

Targeted disruption of the EZH2–EED complex inhibits EZH2-dependent cancer

(2013) Woojin Kim et al.   Nature Chemical Biology

Pan-cancer patterns of somatic copy number alteration

(2013) Travis I Zack et al.   NATURE GENETICS

Mapping genetic interactions in human cancer cells with RNAi and multiparametric phenotyping

(2013) Christina Laufer et al.   NATURE METHODS

Appraising iniparib, the PARP inhibitor that never was—what must we learn?

(2013) Joaquin Mateo et al.   Nature Reviews Clinical Oncology

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Genome Landscapes

(2013) B. Vogelstein et al.   SCIENCE

An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

(2013) D. Rohle et al.   SCIENCE

Cancer Genetics and Epigenetics: Two Sides of the Same Coin?

(2012) Jueng Soo You et al.   CANCER CELL

Mutant p53: one name, many proteins

(2012) W. A. Freed-Pastor et al.   GENES & DEVELOPMENT

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

(2012) Sören Lehmann et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH mutation impairs histone demethylation and results in a block to cell differentiation

(2012) Chao Lu et al.   NATURE

IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

(2012) Sevin Turcan et al.   NATURE

Passenger deletions generate therapeutic vulnerabilities in cancer

(2012) Florian L. Muller et al.   NATURE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Wnt Signaling, Stem Cells, and Cancer of the Gastrointestinal Tract

(2012) A. Schepers et al.   Cold Spring Harbor Perspectives in Biology

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

(2011) Sarat Chandarlapaty et al.   CANCER CELL

Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair

(2011) Arun Gupta et al.   CELL CYCLE

Epigenetic aberrations during oncogenesis

(2011) Maria Hatziapostolou et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe

(2011) P. C. De Witt Hamer et al.   CLINICAL CANCER RESEARCH

Aberrations of EZH2 in Cancer

(2011) A. Chase et al.   CLINICAL CANCER RESEARCH

Searching for synthetic lethality in cancer

(2011) Rachel Brough et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Genome-scale analysis of aberrant DNA methylation in colorectal cancer

(2011) T. Hinoue et al.   GENOME RESEARCH

Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation

(2011) Yongxing Wang et al.   JOURNAL OF CLINICAL INVESTIGATION

Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

(2011) Joyce O'Shaughnessy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis

(2011) F. Fang et al.   Science Translational Medicine

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells

(2011) M Michaelis et al.   Cell Death & Disease

The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo

(2010) V. J. Weston et al.   BLOOD

DNA repair signature is associated with anthracycline response in triple negative breast cancer patients

(2010) A. A. Rodriguez et al.   BREAST CANCER RESEARCH AND TREATMENT

DNA Polymerases as Potential Therapeutic Targets for Cancers Deficient in the DNA Mismatch Repair Proteins MSH2 or MLH1

(2010) Sarah A. Martin et al.   CANCER CELL

Drugging the PI3 Kinome: From Chemical Tools to Drugs in the Clinic

(2010) P. Workman et al.   CANCER RESEARCH

In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models

(2010) D. K. Broz et al.   CARCINOGENESIS

INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect

(2010) Alberto A Chiappori et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

The PI3K Pathway As Drug Target in Human Cancer

(2010) Kevin D. Courtney et al.   JOURNAL OF CLINICAL ONCOLOGY

The DNA Damage Response: Making It Safe to Play with Knives

(2010) Alberto Ciccia et al.   MOLECULAR CELL

Signatures of mutation and selection in the cancer genome

(2010) Graham R. Bignell et al.   NATURE

DNMT3AMutations in Acute Myeloid Leukemia

(2010) Timothy J. Ley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Array-based genomic resequencing of human leukemia

(2010) Y Yamashita et al.   ONCOGENE

The Genetic Landscape of a Cell

(2010) M. Costanzo et al.   SCIENCE

Identification of Nuclear Export Inhibitors with Potent Anticancer Activity In vivo

(2009) S. C. Mutka et al.   CANCER RESEARCH

Ezh2 Orchestrates Gene Expression for the Stepwise Differentiation of Tissue-Specific Stem Cells

(2009) Elena Ezhkova et al.   CELL

DNA Repair in Mammalian Cells

(2009) A. B. Robertson et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

The combined status of ATM and p53 link tumor development with therapeutic response

(2009) H. Jiang et al.   GENES & DEVELOPMENT

Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial

(2009) Ninke Leffers et al.   INTERNATIONAL JOURNAL OF CANCER

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

(2009) Richard L. Piekarz et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

(2009) Pierre Fenaux et al.   LANCET ONCOLOGY

Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor

(2009) Shinji Mizuarai et al.   Molecular Cancer

Discovery, In Vivo Activity, and Mechanism of Action of a Small-Molecule p53 Activator

(2008) Sonia Lain et al.   CANCER CELL

The role of PTEN signaling perturbations in cancer and in targeted therapy

(2008) M Keniry et al.   ONCOGENE

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

(2008) S. Shangary et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA